Streptokinase


Concise Prescribing Info
Indications/Uses
Listed in Dosage.
Dosage/Direction for Use
Adult : IV Acute MI 1.5 million u as a single dose immediately after onset of symptoms. Pulmonary thromboembolism; Arteriovenous occlusions Loading dose: 250,000 u via infusion. Maintenance: 100,000 u/hr for 24-72 hr depending on the condition treated. Duration for cerebral retinal thrombosis: 12 hr. Maintain thrombin clotting time at 2-4 times normal values.
Dosage Details
Intravenous
Acute myocardial infarction
Adult: 1.5 million units as a single dose infused over 1 hr immediately after onset of symptoms.

Intravenous
Pulmonary thromboembolism, Arteriovenous occlusions
Adult: Loading dose: 250,000 units infused over 30 min. Maintenance: 100,000 units/hr for 24-72 hr depending on the condition to be treated. For cerebral retinal thrombosis, 12 hr may be sufficient. Monitor treatment by maintaining thrombin clotting time at 2-4 times normal values.
Child: Loading dose: 2500-4000 units/kg over 30 min, followed by infusion of 500-1000 units/kg/hr, continued until reperfusion occurs, up to 3 days. Initial dose may be estimated by streptokinase resistance test. Monitor treatment by maintaining thrombin clotting time at 2-4 times normal values.
Contraindications
Severe hypertension, recent stroke, cerebral neoplasm, recent history of peptic ulcer disease, ulcerative colitis, pancreatitis, subacute bacterial endocarditis, coagulation defects also due to liver or kidney disease, recent surgery, childbirth. Hypersensitivity, increased risk of cerebral bleeding, trauma. Pregnancy. Active internal bleeding, bleeding GI lesions.
Special Precautions
Mitral stenosis associated with AF. Streptokinase treatment within last 12 mth, use after prolonged or traumatic CPR; diabetic retinopathy. Elderly.
Adverse Reactions
Fever, chills, back pain, abdominal pain, nausea, vomiting, arrhythmia, bruising, rash, pruritus, acute renal failure due to embolism and haemorrhage. Cerebral, peripheral and pulmonary embolism. Allergic reactions, liver enzyme abnormalities, hypotension.
Potentially Fatal: Haemorrhage; anaphylactic shock.
Intra-arterial/Intracoronary/IV/Parenteral: C
Drug Interactions
Antagonistic effects with antifibrinolytic agents e.g. aminocaproic acid.
Potentially Fatal: Anticoagulants, heparin, antiplatelet agents e.g. aspirin and dipyridamole affect platelet function increasing the risk of haemorrhage.
Action
Description: Streptokinase forms a complex with plasminogen which then converts plasminogen to plasmin. Plasmin breaks down clots as well as fibrinogen and other plasma proteins.
Pharmacokinetics:
Absorption: Rapidly cleared from the circulation after IV use.
Excretion: Elimination half-life of streptokinase-activator complex: 23 minutes.
Storage
Store unopened vials at room temperature. Reconstituted solutions should be kept in the refrigerator and used within 24 hr after preparation.
Disclaimer: This information is independently developed by MIMS based on Streptokinase from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to MIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, MIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2020 MIMS. All rights reserved. Powered by MIMS.com
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in